Quidel Corporation (QDEL): Price and Financial Metrics

Quidel Corporation (QDEL)

Today's Latest Price: $196.64 USD

7.33 (3.87%)

Updated Sep 21 11:32am

Add QDEL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

QDEL Stock Summary

  • Price to trailing twelve month operating cash flow for QDEL is currently 43.82, higher than 92.18% of US stocks with positive operating cash flow.
  • Over the past twelve months, QDEL has reported earnings growth of 140.73%, putting it ahead of 91.5% of US stocks in our set.
  • The volatility of Quidel Corp's share price is greater than that of 90.11% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Quidel Corp, a group of peers worth examining would be APPF, MJCO, LMNX, CPRX, and ECOM.
  • QDEL's SEC filings can be seen here. And to visit Quidel Corp's official web site, go to www.quidel.com.
QDEL Daily Price Range
QDEL 52-Week Price Range

QDEL Stock Price Chart Technical Analysis Charts

QDEL Price/Volume Stats

Current price $196.64 52-week high $306.72
Prev. close $189.31 52-week low $55.25
Day low $185.43 Volume 854,170
Day high $197.95 Avg. volume 944,217
50-day MA $224.41 Dividend yield N/A
200-day MA $145.24 Market Cap 8.25B

Quidel Corporation (QDEL) Company Bio

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.

QDEL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$196.64$445.65 135%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Quidel Corp. To summarize, we found that Quidel Corp ranked in the 64th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 136.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for QDEL, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Its equity weight surpasses that of 85.38% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 7.14% of the free cash flow producing stocks we're observing.
  • QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.47% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

DVA, AHPI, BKD, HCSG, and PBH can be thought of as valuation peers to QDEL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

QDEL Latest News Stream

Event/Time News Detail
Loading, please wait...

QDEL Latest Social Stream

Loading social stream, please wait...

View Full QDEL Social Stream

Latest QDEL News From Around the Web

Below are the latest news stories about Quidel Corp that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

Hedge Funds Have Never Been This Bullish On Quidel Corporation (QDEL)

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]

Yahoo | September 15, 2020

Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know

Quidel (QDEL) closed the most recent trading day at $159.39, moving -1.12% from the previous trading session.

Yahoo | September 14, 2020

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

Yahoo | September 14, 2020

Quidel Enters Oversold Territory

Quidel has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Yahoo | September 11, 2020

Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August

Shares of COVID-19 vaccine developer Vaxart (NASDAQ: VXRT) and coronavirus diagnostic test manufacturers Opko Health (NASDAQ: OPK) and Quidel (NASDAQ: QDEL) plunged more than 35% in August, according to data provided by S&P Global Market Intelligence. Vaxart's shares were down 36.9%, Opko's fell 37.1%, and Quidel's dropped 37.7% for the month. Opko's and Quidel's shares are up more than 100% so far in 2020, while Vaxart's have risen a jaw-dropping 1,300%.

Yahoo | September 8, 2020

Read More 'QDEL' Stories Here

QDEL Price Returns

1-mo -18.58%
3-mo -5.13%
6-mo 143.70%
1-year 206.34%
3-year 356.24%
5-year 871.54%
YTD 162.08%
2019 53.69%
2018 12.62%
2017 102.38%
2016 1.04%
2015 -26.69%

Continue Researching QDEL

Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:

Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6731 seconds.